Thalidomide D4

Thalidomide D4 is a deuterated version of the infamous drug Thalidomide, which was initially marketed as a sedative and anti-nausea medication in the late 1950s and early 1960s. However, it was later discovered that Thalidomide was responsible for causing severe birth defects in infants whose mothers had taken the drug during pregnancy. Today, Thalidomide D4 is used primarily as a research tool for studying the pharmacokinetics and metabolism of Thalidomide and similar drugs. Thalidomide D4 is a derivative of Thalidomide that has been modified to contain deuterium atoms, which are heavier forms of hydrogen. This modification allows researchers to track the movement and transformation of Thalidomide D4 in the body using specialized analytical techniques such as mass spectrometry. Additionally, Thalidomide D4 has been shown to have similar pharmacological properties to Thalidomide, making it a useful tool for studying the effects of Thalidomide on cells and tissues. Like Thalidomide, Thalidomide D4 is known to have immunomodulatory and anti-inflammatory properties, and it has been investigated for its potential use in treating a variety of conditions such as cancer, autoimmune diseases, and inflammatory disorders. However, due to its association with birth defects and other serious adverse effects, Thalidomide and its derivatives are highly regulated and only available for use in research and clinical trials.